Post-glomerulonephritis chronic kidney disease: insights and updates

Despite achieving complete or partial remission after the initial glomerulonephritis (GN) episode, patients remain at increased risk for the subsequent development and progression of chronic kidney disease (CKD). Post-GN is a unique CKD entity with clinical phenotypes driven by both disease-specific modifiers and general CKD pathways leading to progressive kidney decline. To minimize progressive renal dysfunction, CKD must be identified and treated in the specific GN context – with distinct dimensions compared to “generic” CKD. In this review, we define post-GN CKD and its phenotypic subtypes, discuss current management, and highlight emerging interventions. Current practice uses serum markers of glomerular filtration, urine protein quantification, and, as indicated, serologic testing and kidney biopsy to identify and risk stratify post-GN CKD subtypes. Core interventions include lifestyle modifications and achieving normotension. In addition to renin–angiotensin–aldosterone inhibition, sodium-glucose co-transporter-2 inhibitors have robust utility in post-GN patients. We discuss how novel targets including endothelin-receptor antagonists, non-steroidal mineralocorticoid receptor blockers, aldosterone synthase inhibitors, and incretin analogs can be tailored to post-GN CKD phenotypes. Finally, we highlight emerging advances including novel serum and urinary biomarkers of kidney injury, genomic and prognostic serologic testing, functional kidney imaging, and artificial intelligence–based machine-learning approaches that detect patients with early kidney dysfunction at heightened risk for rapid progression. These strategies aim to extend glomerular longevity, slow CKD progression, and empower personalized care.

Authors

Institutions

Publication Details

Journal
Rare Kidney Diseases
Published
2026-11-16
DOI
https://doi.org/10.1007/s44531-026-00017-z
Primary Topic
Chronic Kidney Disease and Diabetes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Post-glomerulonephritis chronic kidney disease: insights and updates

Vinay Srinivasan, Parnika Shukla, Sayna Norouzi, Paul E. Hanna et al.
3 links
Rare Kidney Diseases
Chronic Kidney Disease and Diabetes
article

Post-glomerulonephritis chronic kidney disease: insights and updates

Vinay Srinivasan, Parnika Shukla, Sayna Norouzi, Paul E. Hanna, Ginseng Vang, Winn Cashion, Adam Kelly, Sara Bertan
article en

Abstract

Despite achieving complete or partial remission after the initial glomerulonephritis (GN) episode, patients remain at increased risk for the subsequent development and progression of chronic kidney disease (CKD). Post-GN is a unique CKD entity with clinical phenotypes driven by both disease-specific modifiers and general CKD pathways leading to progressive kidney decline. To minimize progressive renal dysfunction, CKD must be identified and treated in the specific GN context – with distinct dimensions compared to “generic” CKD. In this review, we define post-GN CKD and its phenotypic subtypes, discuss current management, and highlight emerging interventions. Current practice uses serum markers of glomerular filtration, urine protein quantification, and, as indicated, serologic testing and kidney biopsy to identify and risk stratify post-GN CKD subtypes. Core interventions include lifestyle modifications and achieving normotension. In addition to renin–angiotensin–aldosterone inhibition, sodium-glucose co-transporter-2 inhibitors have robust utility in post-GN patients. We discuss how novel targets including endothelin-receptor antagonists, non-steroidal mineralocorticoid receptor blockers, aldosterone synthase inhibitors, and incretin analogs can be tailored to post-GN CKD phenotypes. Finally, we highlight emerging advances including novel serum and urinary biomarkers of kidney injury, genomic and prognostic serologic testing, functional kidney imaging, and artificial intelligence–based machine-learning approaches that detect patients with early kidney dysfunction at heightened risk for rapid progression. These strategies aim to extend glomerular longevity, slow CKD progression, and empower personalized care.

Rare Kidney DiseasesVol. 1(1)
Mayo Clinic (US), Medical College of Wisconsin (US), Loma Linda University (US), Cooper University Hospital (US), University of Florida (US), Cooper Medical School of Rowan University (US), Mayo Clinic in Florida (US)
Good health and well-being
Chronic Kidney Disease and Diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon